Everolimus + Everolimus + Paclitaxel

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Transitional Cell Carcinoma

Conditions

Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma

Trial Timeline

Dec 1, 2010 → Apr 24, 2018

NCT ID

NCT01215136

About Everolimus + Everolimus + Paclitaxel

Everolimus + Everolimus + Paclitaxel is a phase 2 stage product being developed by Novartis for Transitional Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01215136. Target conditions include Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma.

What happened to similar drugs?

0 of 9 similar drugs in Transitional Cell Carcinoma were approved

Approved (0) Terminated (3) Active (6)

🔄Vepugratinib + EV + PembrolizumabEli LillyPhase 3

❌AtezolizumabRochePhase 3

🔄vinflunine and best supportive careBristol Myers SquibbPhase 3

🔄padeliporfin VTPICON plc.Phase 3

🔄UGN-101 instillationsUroGen PharmaPhase 3

🔄NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

❌NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01215136	Phase 2	Terminated	Dec 1, 2010	Apr 24, 2018	Transitional Cell Carcinoma

Competing Products

20 competing products in Transitional Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Enfortumab vedotin	Astellas Pharma	Phase 2	35
enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine	Astellas Pharma	Phase 1/2	36
Pemetrexed + Gemcitabine + Platinol	Eli Lilly	Phase 1/2	32
Vepugratinib + EV + Pembrolizumab	Eli Lilly	Phase 3	47
durvalumab and tremelimumab	AstraZeneca	Phase 2	35
Docetaxel + vandetanib + Placebo	AstraZeneca	Phase 2	35
MK-3475 and BCG	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	31
Buparlisib	Novartis	Phase 2	35
BEZ235	Novartis	Phase 2	27
Atezolizumab	Roche	Phase 3	32
Gemcitabine + Cisplatin + Sunitinib Malate	Pfizer	Phase 2	27
Nivolumab/Ipilimumab	Bristol Myers Squibb	Phase 2	31
vinflunine and best supportive care	Bristol Myers Squibb	Phase 3	40
vinflunine	Bristol Myers Squibb	Phase 2	35
Dasatinib	Bristol Myers Squibb	Pre-clinical	26
Docetaxel + Oxaliplatin	Sanofi	Phase 2	35
Cabazitaxel	Sanofi	Phase 2/3	38
Rogaratinib (BAY1163877) + Chemotherapy	Bayer	Phase 2/3	35
CG0070 Adenovirus Vector	CG Oncology	Phase 2/3	27